If there was evidence of effect of genetic instruments for SGLT2 inhibition with unintended phenotypes at a genetic association threshold of 5 × 10−8, multivariable analyses were performed to examine associations between the genetic instruments for SGLT2 inhibition and prostate cancer outcomes, adjusted for genetically proxied phenotype.57 The gene discussed is SLC5A2; the disease is prostate carcinoma.